User profiles for Jonathan Stutters
 | Jonathan StuttersUniversity College London Verified email at ucl.ac.uk Cited by 534 |
[HTML][HTML] Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo …
Background Neurodegeneration is the pathological substrate that causes major disability in
secondary progressive multiple sclerosis. A synthesis of preclinical and clinical research …
secondary progressive multiple sclerosis. A synthesis of preclinical and clinical research …
Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group …
…, D MacManus, RS Samson, J Stutters… - The Lancet …, 2021 - thelancet.com
Background Progressive disability in multiple sclerosis occurs because CNS axons
degenerate as a late consequence of demyelination. In animals, retinoic acid receptor RXR-gamma …
degenerate as a late consequence of demyelination. In animals, retinoic acid receptor RXR-gamma …
Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study
…, MP Sormani, K Selmaj, J Stutters… - Multiple Sclerosis …, 2022 - journals.sagepub.com
Background: The envelope protein of human endogenous retrovirus W (HERV-W-Env) is
expressed by macrophages and microglia, mediating axonal damage in chronic active MS …
expressed by macrophages and microglia, mediating axonal damage in chronic active MS …
Amiloride, fluoxetine or riluzole to reduce brain volume loss in secondary progressive multiple sclerosis: the MS-SMART four-arm RCT
Background Neuroprotective drugs are needed to slow or prevent neurodegeneration and
disability accrual in secondary progressive multiple sclerosis. Amiloride, fluoxetine and …
disability accrual in secondary progressive multiple sclerosis. Amiloride, fluoxetine and …
Association of slowly expanding lesions on MRI with disability in people with secondary progressive multiple sclerosis
A Calvi, FP Carrasco, C Tur, DT Chard, J Stutters… - Neurology, 2022 - AAN Enterprises
Background and Objective To explore the relationship between slowly expanding lesions (SELs)
on MRI and disability in secondary progressive multiple sclerosis (SPMS). Methods We …
on MRI and disability in secondary progressive multiple sclerosis (SPMS). Methods We …
Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical …
Introduction The major unmet need in multiple sclerosis (MS) is for neuroprotective therapies
that can slow (or ideally stop) the rate of disease progression. The UK MS Society Clinical …
that can slow (or ideally stop) the rate of disease progression. The UK MS Society Clinical …
Predicting disability progression and cognitive worsening in multiple sclerosis using patterns of grey matter volumes
Objective In multiple sclerosis (MS), MRI measures at the whole brain or regional level are
only modestly associated with disability, while network-based measures are emerging as …
only modestly associated with disability, while network-based measures are emerging as …
[HTML][HTML] Slowly expanding lesions relate to persisting black-holes and clinical outcomes in relapse-onset multiple sclerosis
Background Slowly expanding lesions (SELs) are MRI markers of chronic active lesions in
multiple sclerosis (MS). T1-hypointense black holes, and reductions in magnetization transfer …
multiple sclerosis (MS). T1-hypointense black holes, and reductions in magnetization transfer …
Longitudinal metabolite changes in progressive multiple sclerosis: a study of 3 potential neuroprotective treatments
Background 1 H‐magnetic resonance spectroscopy ( 1 H‐MRS) may provide a direct index
for the testing of medicines for neuroprotection and drug mechanisms in multiple sclerosis (…
for the testing of medicines for neuroprotection and drug mechanisms in multiple sclerosis (…
Remyelination varies between and within lesions in multiple sclerosis following bexarotene
…, DR Altmann, B Kanber, J Stutters… - Annals of clinical …, 2022 - Wiley Online Library
Objective In multiple sclerosis chronic demyelination is associated with axonal loss, and
ultimately contributes to irreversible progressive disability. Enhancing remyelination may slow, …
ultimately contributes to irreversible progressive disability. Enhancing remyelination may slow, …
